Sumitomo Pharma Co., Ltd.'s Form 4 filing
Myovant Sciences Ltd. (MYOV) · filed Sep 8, 2021
- Accession no.
- 0000899243-21-035342
- Filed
- Sep 8, 2021, 5:00 PM ET
- Trade date
- Sep 3-7, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $1.71M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sumitomo Pharma Co., Ltd.CIK 0001446601 | 10% Owner |
| Sumitovant Biopharma Ltd.CIK 0001798244 | 10% Owner |
| Sumitomo Chemical Co., Ltd.CIK 0001798550 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 | Common Stock | PPurchaseAcquired | +29,822 | $26.74F2 | +$797,383.62 | 49,260,700 | Indirect | |
| Sep 3, 2021 | Common Stock | PPurchaseAcquired | +1,378 | $27.29F4 | +$37,609.89 | 49,262,078 | Indirect | |
| Sep 7, 2021 | Common Stock | PPurchaseAcquired | +28,287 | $26.08F6 | +$737,679.7 | 49,290,365 | Indirect | |
| Sep 7, 2021 | Common Stock | PPurchaseAcquired | +4,913 | $27.12F8 | +$133,249.4 | 49,295,278 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades ranging from $26.19 to $27.18 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
The transaction was executed in multiple trades ranging from $27.25 to $27.32 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F6
The transaction was executed in multiple trades ranging from $25.79 to $26.76 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F8
The transaction was executed in multiple trades ranging from $26.81 to $27.35 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.